NeuroDerm

Drug-device Combination Solutions for Central Nervous System Disorders

Health Tech & Life Sciences
Acquired by Mitsubishi Tanabe Pharma Corporation on Jul, 2017

Company Overview

Snapshot

Founded in March 2003, NeuroDerm operates with 51–200 employees. The company raised $63.5 million across 3 funding rounds from 2 investors. NeuroDerm was acquired by Mitsubishi Tanabe Pharma Corporation in July 2017 for $1.1 billion in cash.

Business overview

NeuroDerm specializes in developing drug-device combination solutions for central nervous system disorders. The company integrates proprietary pharmaceutical formulations, advanced delivery systems, and digital health solutions to improve patient quality of life. Its flagship product, ND0612, is in late-stage development for Parkinson's disease patients experiencing motor fluctuations, designed to provide continuous subcutaneous infusion of levodopa/carbidopa. NeuroDerm operates within the Health Tech & Life Sciences sector, focusing on pharmaceuticals, neurology, and medical devices.

Strategic signal

In January 2023, NeuroDerm announced highly positive results from its pivotal Phase III BouNDless trial, evaluating ND0612 for Parkinson's disease patients with motor fluctuations. This successful trial outcome validates the efficacy of their drug-device combination solution and signals significant progress in addressing a critical unmet need for Parkinson's patients, potentially paving the way for regulatory approvals and market entry.

Company Intelligence Q&A

What was a significant financial event for NeuroDerm in 2017?
In July 2017, NeuroDerm entered a definitive agreement to be acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 billion in cash.
What was the outcome of NeuroDerm's Phase III trial for ND0612?
In January 2023, NeuroDerm announced highly positive results from the pivotal Phase III BouNDless trial, which evaluated ND0612 in Parkinson's disease patients with motor fluctuations.
When did NeuroDerm initiate its Phase 3 clinical trial for ND0612 in the United States?
In August 2019, NeuroDerm initiated a Phase 3 clinical trial in the United States to evaluate continuous subcutaneous carbidopa/levodopa (ND0612) for Parkinson's disease with motor fluctuations.
What was the outcome of NeuroDerm's Nasdaq IPO in November 2014?
In November 2014, NeuroDerm's Nasdaq IPO disappointed, as reported by Globes. The company was set for a $60-82 million Nasdaq IPO.
What was a key development for NeuroDerm in March 2017?
In March 2017, NeuroDerm saw its stock jump following successful trial results, as reported by Globes.

External links